Navigation Links
Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Date:3/13/2008

s, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythematosus and other undisclosed indications.

Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, the risk that the Company does not achieve the financial and operating
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
3. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
4. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. ... phosphorous through the activities in the soil or in ... to the stress on reducing environmental pollution and on ... defines and segments the bio fertilizers market with analysis ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Eckert & ... Mass Spectrometry (AMS) services to the pharmaceutical and biotech ... joined the company in the position of Director of ... of broad and valuable experience in drug metabolism and ...
(Date:1/22/2015)... 22, 2015 GEA Niro Soavi the ... laboratory homogenizer, the PandaPLUS 2000, which is ideal for ... and cell disruption . This compact laboratory homogenizer ... juices, liquid food, food additives and ingredients as well ...
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... Corp.,(Nasdaq: GENZ ) announced today that it ... for the treatment of Hunter syndrome.,Elaprase is an ... Inc., and Genzyme is commercializing the product in ... with Shire. Genzyme intends,to launch Elaprase this quarter, ...
... Inc. (Nasdaq:,BIOD) today announced that Solomon Steiner, Chairman and CEO ... 2007 in San,Francisco, CA on October 11th at 11:00 AM ... live audio webcast of the,presentation in the investor relations section ... presentation will be available for,14 days. About Biodel Inc. ...
... new products, Skin Optimizer and Hyaluronic Acid Complex, promote ... skin and ... Formulas, recognized in,July by Nutrition Business Journal, selected BioCell Collagen ... the,effectiveness of two new Jarrow Formulas products -- Skin Optimizer ...
Cached Biology Technology:Genzyme Receives Approval to Market Elaprase(R) in Japan 2Genzyme Receives Approval to Market Elaprase(R) in Japan 3Genzyme Receives Approval to Market Elaprase(R) in Japan 4Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007 2Jarrow Formulas Launches New Products Featuring BioCell Collagen II(R) 2
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... make it easier to detect and prevent counterfeit microcircuits ... the agency started performing an in-house microcircuit anti-counterfeit initiative ... of purchased microcircuits while increasing their reliability throughout the ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in this market ... applications. Chemical sensors help in recording of patient data ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Clinicians and scientists working in the Southampton Centre ... Southampton,s University Hospitals Trust (SUHT) and the University ... the city,s world-leading nutrition and respiratory research facilities. ... the Government,s record 800m investment in NHS and ...
... agriculture, causing famine and increasing consumer food costs. Now, researchers at the ... completed two drought simulators designed to test the effects of water deficiency ... Research and Extension Center east of Columbia. , , ... , , ...
... Medicine has been awarded a $3.4 million grant over four ... the National Institutes of Health (NIH) to begin the largest ... for disease is revealed in a lab, and then entered ... in the clinical care setting. Using DNA and ...
Cached Biology News:Southampton researchers awarded $28 million to progress pioneering nutrition and respiratory research 2University of Missouri completes first drought simulator 2University of Missouri completes first drought simulator 3Mount Sinai receives $3.4 million for largest study of personalized medicine in the clinical setting 2Mount Sinai receives $3.4 million for largest study of personalized medicine in the clinical setting 3
... Shakers combine high durability and performance ... The patented triple-counterbalanced heavy-duty mechanism ... run with heavy out-of-balance loads. ... contamination. The heavy stainless steel ...
... The Cellject Uno Electroporator is a ... producing optimum efficiencies in bacterial and ... selects one of two voltages and ... four mm cuvettes. On pressing the ...
MOUSE ANTI GTP BINDING PROTEIN...
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
Biology Products: